



10th Anniversary of Biomedicines—Advances in Chronic Obstructive Pulmonary Disease (COPD)

Guest Editor:

Prof. Dr. Alice M Turner

Centre for Translational
Inflammation Research,
University of Birmingham,
Birmingham, UK

Deadline for manuscript
submissions:

closed (30 April 2023)

Message from the Guest Editor

This Special Issue focuses on recent advances in diagnostics and therapeutics for COPD, which represents an increasing medical and economic burden worldwide. Understanding is now growing about public health reasons for this, such as air pollution and occupation, as well as the commonly known risk factor of cigarette smoking. Furthermore, knowledge of treatment has advanced from the generic to the specific, with newer treatments targeting pathophysiological endotypes of COPD rather than the generic management of airflow obstruction. We also understand the range of co-morbidities that COPD patients exhibit, and we are beginning to delineate shared pathophysiology and routes to therapy. Nevertheless, there remain many unanswered questions in COPD, from how to address etiological risk factors or generic treatments, particularly in resource-poor environments, to patient selection for high-cost targeted therapies, such as monoclonal antibodies. We invite the submission of research articles that will improve our knowledge on these topics, either through original research or reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)